A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Holkova B, Perkins E, Sokol L, Richards K, Parekh S, Elstrom R, Badros A, Espinoza-Delgado I, Schell M, Kimball A, Tombes M, Shrader E, Sankala H, Coppola D, Kmieciak M, Sullivan D, Roberts J, Grant S. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. Blood 2011, 118: 779. DOI: 10.1182/blood.v118.21.779.779.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaRefractory diffuse large B-cell lymphomaMantle cell lymphomaLarge B-cell lymphomaB-cell lymphomaResponse rateCohort BCohort ACell lymphomaDay 1Common treatment-related adverse eventsPan-HDAC inhibitor vorinostatTreatment-related adverse eventsCommon grade 3Peripheral sensory neuropathyPhase II studySpeakers bureauECOG performance scorePhase II trialSchedule of administrationPhase I studiesCombination of bortezomibNumerous preclinical studiesB-cell malignanciesProteasome inhibitor bortezomibPhase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. Clinical Cancer Research 2011, 17: 3388-3397. PMID: 21447728, PMCID: PMC3096752, DOI: 10.1158/1078-0432.ccr-10-2876.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityCombination of bortezomibFebrile neutropeniaPharmacodynamic studiesDay 1Refractory B-cell neoplasmsElevated aspartate aminotransferase levelsCommon hematologic toxicityCommon nonhematologic toxicitiesPhase II studyRefractory multiple myelomaPhase I studiesAspartate aminotransferase levelsB-cell malignanciesB-cell neoplasmsHematologic toxicityIntravenous pushNonhematologic toxicityStable diseaseAminotransferase levelsI trialII studyPartial responseComplete responseDose escalation